TISIDB

Summary
Symbol	FAS
Name	Fas cell surface death receptor
Aliases	CD95; APO-1; TNF receptor superfamily member 6; FAS1; TNFRSF6; tumor necrosis factor receptor superfamily, m ......
Chromosomal Location	10q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Secreted.; SUBCELLULAR LOCATION: Isoform 3: Secreted.; SUBCELLULAR LOCATION: Isoform 4: Secreted.; SUBCELLULAR LOCATION: Isoform 5: Secreted.; SUBCELLULAR LOCATION: Isoform 6: Secreted.
Domain	PF00531 Death domain PF00020 TNFR/NGFR cysteine-rich region
Function	Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro).

> Gene Ontology [ TOP ]
Biological Process	GO:0001776 leukocyte homeostasis GO:0002237 response to molecule of bacterial origin GO:0002250 adaptive immune response GO:0002260 lymphocyte homeostasis GO:0002377 immunoglobulin production GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002695 negative regulation of leukocyte activation GO:0003014 renal system process GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006924 activation-induced cell death of T cells GO:0006925 inflammatory cell apoptotic process GO:0007159 leukocyte cell-cell adhesion GO:0007623 circadian rhythm GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors GO:0009612 response to mechanical stimulus GO:0009636 response to toxic substance GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0010226 response to lithium ion GO:0010950 positive regulation of endopeptidase activity GO:0010952 positive regulation of peptidase activity GO:0019724 B cell mediated immunity GO:0030098 lymphocyte differentiation GO:0030099 myeloid cell differentiation GO:0030217 T cell differentiation GO:0031334 positive regulation of protein complex assembly GO:0031960 response to corticosteroid GO:0032459 regulation of protein oligomerization GO:0032461 positive regulation of protein oligomerization GO:0032462 regulation of protein homooligomerization GO:0032464 positive regulation of protein homooligomerization GO:0032496 response to lipopolysaccharide GO:0033077 T cell differentiation in thymus GO:0033209 tumor necrosis factor-mediated signaling pathway GO:0034612 response to tumor necrosis factor GO:0036295 cellular response to increased oxygen levels GO:0036296 response to increased oxygen levels GO:0038034 signal transduction in absence of ligand GO:0042110 T cell activation GO:0042113 B cell activation GO:0043029 T cell homeostasis GO:0043254 regulation of protein complex assembly GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043383 negative T cell selection GO:0043410 positive regulation of MAPK cascade GO:0044089 positive regulation of cellular component biogenesis GO:0045058 T cell selection GO:0045060 negative thymic T cell selection GO:0045061 thymic T cell selection GO:0045619 regulation of lymphocyte differentiation GO:0045637 regulation of myeloid cell differentiation GO:0045862 positive regulation of proteolysis GO:0048511 rhythmic process GO:0048536 spleen development GO:0048545 response to steroid hormone GO:0048872 homeostasis of number of cells GO:0050864 regulation of B cell activation GO:0050865 regulation of cell activation GO:0050866 negative regulation of cell activation GO:0050869 negative regulation of B cell activation GO:0051249 regulation of lymphocyte activation GO:0051250 negative regulation of lymphocyte activation GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051384 response to glucocorticoid GO:0051402 neuron apoptotic process GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0055093 response to hyperoxia GO:0070227 lymphocyte apoptotic process GO:0070228 regulation of lymphocyte apoptotic process GO:0070230 positive regulation of lymphocyte apoptotic process GO:0070231 T cell apoptotic process GO:0070265 necrotic cell death GO:0070266 necroptotic process GO:0070482 response to oxygen levels GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070997 neuron death GO:0071214 cellular response to abiotic stimulus GO:0071241 cellular response to inorganic substance GO:0071248 cellular response to metal ion GO:0071260 cellular response to mechanical stimulus GO:0071285 cellular response to lithium ion GO:0071356 cellular response to tumor necrosis factor GO:0071453 cellular response to oxygen levels GO:0071455 cellular response to hyperoxia GO:0071496 cellular response to external stimulus GO:0071593 lymphocyte aggregation GO:0071594 thymocyte aggregation GO:0071887 leukocyte apoptotic process GO:0097049 motor neuron apoptotic process GO:0097191 extrinsic apoptotic signaling pathway GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand GO:0097284 hepatocyte apoptotic process GO:0097296 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097300 programmed necrotic cell death GO:0097527 necroptotic signaling pathway GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902105 regulation of leukocyte differentiation GO:1903706 regulation of hemopoiesis GO:1904019 epithelial cell apoptotic process GO:2000106 regulation of leukocyte apoptotic process GO:2000108 positive regulation of leukocyte apoptotic process GO:2000116 regulation of cysteine-type endopeptidase activity GO:2001056 positive regulation of cysteine-type endopeptidase activity GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001237 negative regulation of extrinsic apoptotic signaling pathway GO:2001238 positive regulation of extrinsic apoptotic signaling pathway GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001267 regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:2001269 positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
Molecular Function	GO:0005031 tumor necrosis factor-activated receptor activity GO:0005035 death receptor activity
Cellular Component	GO:0009897 external side of plasma membrane GO:0031264 death-inducing signaling complex GO:0031265 CD95 death-inducing signaling complex GO:0045121 membrane raft GO:0098552 side of membrane GO:0098589 membrane region GO:0098857 membrane microdomain

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04010 MAPK signaling pathway hsa04060 Cytokine-cytokine receptor interaction hsa04115 p53 signaling pathway hsa04210 Apoptosis hsa04650 Natural killer cell mediated cytotoxicity hsa04668 TNF signaling pathway
Reactome	R-HSA-109581: Apoptosis R-HSA-5218900: CASP8 activity is inhibited R-HSA-5357769: Caspase activation via extrinsic apoptotic signalling pathway R-HSA-73887: Death Receptor Signalling R-HSA-69416: Dimerization of procaspase-8 R-HSA-75157: FasL/ CD95L signaling R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-140534: Ligand-dependent caspase activation R-HSA-5357801: Programmed Cell Death R-HSA-5213460: RIPK1-mediated regulated necrosis R-HSA-5218859: Regulated Necrosis R-HSA-3371378: Regulation by c-FLIP R-HSA-5675482: Regulation of necroptotic cell death R-HSA-162582: Signal Transduction R-HSA-5633008: TP53 Regulates Transcription of Cell Death Genes R-HSA-6803211: TP53 Regulates Transcription of Death Receptors and Ligands R-HSA-3700989: Transcriptional Regulation by TP53

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04010 MAPK signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04115 p53 signaling pathway
hsa04210 Apoptosis
hsa04650 Natural killer cell mediated cytotoxicity
hsa04668 TNF signaling pathway

Reactome

R-HSA-109581: Apoptosis
R-HSA-5218900: CASP8 activity is inhibited
R-HSA-5357769: Caspase activation via extrinsic apoptotic signalling pathway
R-HSA-73887: Death Receptor Signalling
R-HSA-69416: Dimerization of procaspase-8
R-HSA-75157: FasL/ CD95L signaling
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-140534: Ligand-dependent caspase activation
R-HSA-5357801: Programmed Cell Death
R-HSA-5213460: RIPK1-mediated regulated necrosis
R-HSA-5218859: Regulated Necrosis
R-HSA-3371378: Regulation by c-FLIP
R-HSA-5675482: Regulation of necroptotic cell death
R-HSA-162582: Signal Transduction
R-HSA-5633008: TP53 Regulates Transcription of Cell Death Genes
R-HSA-6803211: TP53 Regulates Transcription of Death Receptors and Ligands
R-HSA-3700989: Transcriptional Regulation by TP53

Summary
Symbol	FAS
Name	Fas cell surface death receptor
Aliases	CD95; APO-1; TNF receptor superfamily member 6; FAS1; TNFRSF6; tumor necrosis factor receptor superfamily, m ......
Chromosomal Location	10q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FAS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between FAS and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26136424	Colon Carcinoma	Promote immunity (T cell function)	Using an orthotopic colon cancer mouse model, we demonstrated that tumor-infiltrating cytotoxic T lymphocytes are FasL(+) and that FasL-mediated cancer immune surveillance is essential for colon carcinoma growth control in vivo. Our findings determine that H3K9me3 of the FAS promoter is a dominant mechanism underlying FAS silencing and resultant colon carcinoma immune evasion and progression.
10706715	Lung Carcinoma	Promote immunity	The finding of up-regulated CD95 expression on tumor cells placed in vivo suggests that a CD95-based mechanism plays a role in tumor immunity at early stages of tumor growth. Consequently, the progressive down-regulation of CD95 expression during tumor progression may indeed be an escape mechanism as previously reported.
24487434	Diffuse Large B Cell Lymphoma	Promote immunity (T cell function); increase the efficacy of immunotherapy	Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Impairment of T cell control results in rapid development of DLBCL-like disease, which can be eradicated by polyclonal CD8(+) T cells in a T cell receptor-, CD28- and Fas ligand-dependent manner.
19265159	Lung carcinoma	Inhibit immunity	Therefore, our results demonstrate that Fas signal can promote lung cancer growth by recruiting MDSC via cancer cell-derived PGE(2), thus providing new mechanistic explanation for the role of inflammation in cancer progression and immune escape.
23390011	Colon Carcinoma	Inhibit immunity (infiltration)	PGE2 signals through four different receptors (EP1-EP4) and targeting individual receptor(s) may avoid these side effects, while retaining significant anticancer benefits. This antitumor effect was associated with reduced Fas ligand expression and attenuated tumor-induced immune suppression. In particular, tumor infiltration by CD4(+) CD25(+) Foxp3(+) regulatory T cells was decreased, whereas the cytotoxic activity of isolated splenocytes against CT26 cells was increased.
21278794	Breast Carcinoma	Promote immunity	Secretion of pro-inflammatory cytokines by the senescent cells, particularly TNF-α and IFN-γ, mediates Fas upregulation. Indeed, treatment of proliferating cancer cell lines with TNF-α and IFN-γ, upregulates Fas expression, while blocking TNF-α and IFN-γ by using neutralizing antibodies, decreases Fas expression in senescent cells. We also demonstrate that NF-κB has a central role in controlling the senescence-associated secretory phenotype (SASP) by the premature senescent cells, and that TNF-α and IFN-γ, transcriptionally controlled by NF-κB, are the main mediators of Fas upregulation. Our data suggest the existence of an NF-κB-dependent autocrine loop, mediated by TNF-α and IFN-γ, responsible for expression of Fas on the surface of senescent cells, and for their killing.
19692638	Head and Neck Squamous Cell Carcinoma	Inhibit immunity (T cell function)	Sera of patients with cancer contain membraneous microvesicles (MV) able to induce apoptosis of activated T cells by activating the Fas/Fas ligand pathway.
24808361	Renal Cell Carcinoma	Promote immunity	We demonstrate in this study in two murine tumor models that Treg and MDSC loss within the tumor microenvironment after IL-2/αCD40 occurs through a Fas-dependent cell death pathway. Among tumor-infiltrating leukocytes, CD8(+) T cells, neutrophils, and immature myeloid cells expressed Fas ligand after treatment. Fas was expressed by tumor-associated Tregs and immature myeloid cells, including MDSCs. Tregs and MDSCs in the tumor microenvironment expressed active caspases after IL-2/αCD40 therapy and, in contrast with effector T cells, Tregs significantly downregulated Bcl-2 expression. Adoptive transfer of Fas-deficient Tregs or MDSCs into wild-type, Treg-, or MDSC-depleted hosts resulted in the persistence of Tregs or MDSCs and the loss of antitumor efficacy in response to IL-2/αCD40. These results demonstrate the importance of Fas-mediated Treg/MDSC removal for successful antitumor immunotherapy.
25012502	Pancreatic ductal adenocarcinoma	Promote immunity (T cell function)	Tumor cells treated with sublethal doses of RLH ligands upregulated Fas and MHC-I expression and were effectively sensitized towards Fas-mediated apoptosis and cytotoxic T lymphocyte (CTL)-mediated lysis.
24004671	Plasma Cell Myeloma	Promote immunity (T cell function)	Further analyses revealed that adhesion to accessory cells downregulated Fas and upregulated the caspase-3 inhibitor survivin in multiple myeloma cells. Reconstitution of Fas expression with bortezomib enhanced the CTL-mediated lysis of multiple myeloma cells.
21321117	Chronic myelogenous leukemia	Promote immunity (NK cell function)	Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells. Taken together, these data show that IL-32α stimulates Fas and ULBP2 expression via activation of p38 MAPK, which increases NK susceptibility of CML cells. Enhanced NK cell susceptibility of CML cells by IL-32α overexpression may improve the efficiency of NK cell-based immunotherapy.
15981207	Cervical Carcinoma	Promote immunity (T cell function)	Our results demonstrated that chimeric CRT/E7 DNA vaccine resulted in control of tumors with downregulated Fas expression, highlighting the importance of the Fas-FasL pathway in the potent antitumor effect of antigen-specific CD8+ cytotoxic T lymphocytes and the role of Fas as part of in vivo tumor evasion.
29123081	Melanoma	Inhibit immunity	Apoptosis of tumor-infiltrating lymphocytes can be prevented by interrupting the Fas/Fas-ligand axis, and is triggered by polymorphonuclear-myeloid-derived suppressor cells, which express high levels of Fas-ligand and are enriched in TiRP tumors. Blocking Fas-ligand increases the anti-tumor efficacy of adoptive T-cell therapy in TiRP tumors, and increases the efficacy of checkpoint blockade in transplanted tumors.
22027835	Colon Carcinoma	Promote immunity	Binding of TRAIL and CD95 ligand to their cognate receptors primarily leads to formation of a complex comprising the receptor, FADD, and caspase-8, referred to as the death-inducing signaling complex (DISC).
21622855	Melanoma	Promote immunity	Remarkably, in vivo protection of T cells from TCR-mediated apoptosis by an adenovirus engineered to produce soluble Fas resulted in a dramatic reduction in tumor growth.
25248763	E.G7-OVA tumors	Promote immunity (T cell function)	Bone marrow chimeras revealed that IFNgammaR1 and Fas expression on immune cells was most critical for rejection, and SPLNX increased the frequency of activated macrophages (Mvarphi) within intraocular tumors in an IFNgamma- and Fas/FasL-dependent manner, suggesting an immune cell target of IFNgamma and Fas. As depletion of Mvarphis limited CD8 T cell-mediated rejection of intraocular tumors in SPLNX mice, our data support a model in which IFNgamma- and Fas/FasL-dependent activation of intratumoral Mvarphis by CD8(+) T cells promotes severe intraocular inflammation that indirectly eliminates intraocular tumors by inducing phthisis, and suggests that immunosuppressive mechanisms that maintain ocular IP interfere with the interaction between CD8(+) T cells and Mvarphis to limit the immunosurveillance of intraocular tumors.
23341634	fibrosarcoma; Melanoma	Promote immunity	Complete tumor rejection required IFNgamma-regulated Fas by the tumor stroma. Therefore, T(E) cells lacking IFNgamma or FasL cannot prevent progression of antigenic cancer because the tumor stroma escapes destruction if its Fas expression is down-regulated.

Summary
Symbol	FAS
Name	Fas cell surface death receptor
Aliases	CD95; APO-1; TNF receptor superfamily member 6; FAS1; TNFRSF6; tumor necrosis factor receptor superfamily, m ......
Chromosomal Location	10q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FAS in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FAS
Name	Fas cell surface death receptor
Aliases	CD95; APO-1; TNF receptor superfamily member 6; FAS1; TNFRSF6; tumor necrosis factor receptor superfamily, m ......
Chromosomal Location	10q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FAS in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.01	0.983
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.556	0.683
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.418	0.707
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.432	0.293
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.942	0.487
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.217	0.903
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.063	0.878
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.29	0.822
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.381	0.801
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.326	0.842
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.404	0.872
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.306	0.0306

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FAS in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	FAS
Name	Fas cell surface death receptor
Aliases	CD95; APO-1; TNF receptor superfamily member 6; FAS1; TNFRSF6; tumor necrosis factor receptor superfamily, m ......
Chromosomal Location	10q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FAS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FAS
Name	Fas cell surface death receptor
Aliases	CD95; APO-1; TNF receptor superfamily member 6; FAS1; TNFRSF6; tumor necrosis factor receptor superfamily, m ......
Chromosomal Location	10q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FAS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FAS. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FAS
Name	Fas cell surface death receptor
Aliases	CD95; APO-1; TNF receptor superfamily member 6; FAS1; TNFRSF6; tumor necrosis factor receptor superfamily, m ......
Chromosomal Location	10q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FAS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FAS
Name	Fas cell surface death receptor
Aliases	CD95; APO-1; TNF receptor superfamily member 6; FAS1; TNFRSF6; tumor necrosis factor receptor superfamily, m ......
Chromosomal Location	10q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FAS expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FAS
Name	Fas cell surface death receptor
Aliases	CD95; APO-1; TNF receptor superfamily member 6; FAS1; TNFRSF6; tumor necrosis factor receptor superfamily, m ......
Chromosomal Location	10q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FAS and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FAS
Name	Fas cell surface death receptor
Aliases	CD95; APO-1; TNF receptor superfamily member 6; FAS1; TNFRSF6; tumor necrosis factor receptor superfamily, m ......
Chromosomal Location	10q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FAS collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FAS